What Are They, How Do They Work, What Are They Used For, and More
Author: Ashley Mauldin, MSN, APRN, FNP-BC
Editors: Antonella Melani, MD, Nimmit Vyas, PharmD
Illustrator: Jillian Dunbar
What is a phosphodiesterase inhibitor?
Phosphodiesterase inhibitors are a class of medications that promote blood vessel dilation (vasodilation) and smooth muscle relaxation in certain parts of the body, such as the heart, lungs, and genitals. Phosphodiesterases are a diverse family of enzymes that play a key role in regulating cell functions by indirectly increasing the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), both of which are “second messengers” that regulate the primary effects of hormones and neurotransmitters.
How do phosphodiesterase inhibitors work?
Phosphodiesterase inhibitors work by inhibiting the phosphodiesterase enzymes, thus preventing them from breaking down cAMP and cGMP molecules in the cell. The production of cAMP and cGMP are regulated by a molecule called nitric oxide, and their function is to help regulate physiological processes by decreasing the levels of calcium in the cell. Ultimately, cAMP and cGMP are broken down by phosphodiesterase enzymes.
What happens when phosphodiesterase is inhibited?
When phosphodiesterase is inhibited, it is not able to break down the cAMP and cGMP. Thus, their levels inside the cell increase, which in turn leads to a decrease in the levels of calcium in the cell. Ultimately, this leads to vasodilation and smooth muscle relaxation in their target tissues.
What are phosphodiesterase inhibitors used for?
Phosphodiesterase inhibitors are classified based on which specific phosphodiesterase enzyme they target. There are 11 families of phosphodiesterase enzymes and PDE inhibitors for each. Among these, the most widely used are four types of phosphodiesterase inhibitors: phosphodiesterase type 5 inhibitors (PDE5 inhibitor), phosphodiesterase type 4 inhibitors (PDE4 inhibitor), phosphodiesterase type 3 inhibitors (PDE3 inhibitor), and nonspecific inhibitors.
PDE5 inhibitors work by increasing the levels of cGMP and specifically target the penis and the lungs. PDE5 inhibitors can be used to treat erectile dysfunction by inducing smooth muscle relaxation and increasing the blood flow to the penis, leading to an erection. Additionally, PDE5 inhibitors trigger pulmonary vasodilation, helping to regulate the pulmonary perfusion and pressure, thus they can be used to treat pulmonary hypertension when given at a lower dose compared to erectile dysfunction.PDE4 inhibitors
PDE4 inhibitors work by increasing the levels of cAMP. They specifically target the airways, the skin and immune system, and the brain. PDE4 inhibitors work by causing smooth muscle relaxation in the airways, making them useful in the treatment of pulmonary diseases, such as asthma and chronic obstructive pulmonary disease. PDE4 inhibitors can also be used to treat inflammatory conditions that may affect the skin or other tissues, such as psoriasis, atopic dermatitis, inflammatory bowel disease, and rheumatoid arthritis. There is currently research being conducted on PDE4 inhibitors being used in the treatment of mental conditions, such as depression and anxiety.
PDE3 inhibitors work by increasing the levels of cAMP. PDE3 inhibitors are typically used for cardiovascular diseases. In the heart, they help to increase cardiac contractility, or the ability of the heart to beat. They also relax vascular and airway smooth muscle, making them useful in the treatment of heart failure. In addition, PDE3 inhibitors can prevent platelet aggregation into clots, and can thus be used to prevent and treat myocardial infarction (heart attack). Finally, PDE3 inhibitors can trigger vasodilation of peripheral blood vessels and can be used to treat intermittent claudication, which is a cramping in the legs due to a decreased blood flow.Nonspecific inhibitors
Nonspecific inhibitors work by decreasing the destruction of the cAMP by any phosphodiesterase enzyme. They mainly induce mild dilation of the bronchioles of the lungs and help reduce airway inflammation. Nonspecific phosphodiesterase inhibitors are used in the treatment of chronic obstructive pulmonary disease, as well as for short term and long term management of asthma.
What are some examples of common phosphodiesterase inhibitors?
The most common PDE4 inhibitors are roflumilast, apremilast, and ibudilast.
Is Viagra a phosphodiesterase inhibitor?
Viagra is a PDE5 inhibitor most often used for the treatment of erectile dysfunction. Viagra has also been useful in the treatment of pulmonary hypertension for both short term and long term use when given at a lower dose compared to the dosages prescribed for erectile dysfunction. Viagra has a low number of side effects and is considered relatively safe for individuals with heart disease. However, it’s important to note that the use of Viagra taken along with nitrates can lead to a reduction in blood pressure and is contraindicated.
Are phosphodiesterase 5 inhibitors a competitive inhibitor?
Phosphodiesterase type 5 inhibitors are competitive and reversible inhibitors. When a PDE5 inhibitor is used, it competitively binds to PDE5 to stop it from breaking down cGMP. PDE5 inhibitors are considered reversible because they bind to PDE5 for a limited amount of time. With the decrease in the levels of the cGMP, this will reverse the smooth muscle relaxation in the penis, which will end the erection.
Is caffeine a phosphodiesterase inhibitor?
Caffeine is a phosphodiesterase inhibitor that has been shown to increase the levels of cAMP in the cell thus leading to smooth muscle relaxation. Caffeine is a weak inhibitor, but variations of caffeine including theophylline have been introduced as treatments for pulmonary disease.
Are methylxanthines phosphodiesterase inhibitors?
Methylxanthines are among the first phosphodiesterase inhibitors to be discovered, and are nonspecific. The most common methylxanthine is theophylline, which is commonly used for short or long term treatment of different types of pulmonary diseases, such as asthma. Methylxanthines can help to induce bronchodilation and reduce airway inflammation.
What are the side effects of phosphodiesterase inhibitors?
Common side effects of PDE5 inhibitors include headache, nasal congestion, dyspepsia and flushing. A potential rare side effect of PDE5 inhibitors is priapism, or an erection lasting longer than 4 hours. Priapism is a medical emergency that requires immediate intervention. First line treatment is oral terbutaline or pseudoephedrine. If the priapism persists, needle aspiration of the blood in the penis, as well as an intracavernous injection of phenylephrine, may be needed.
Potential side effects of PDE4 inhibitors are headaches, nausea, and diarrhea.
Side effects of nonspecific inhibitors include upset stomach, diarrhea, headaches, and restlessness.
What are the most important facts to know about phosphodiesterase inhibitors?
Phosphodiesterase inhibitors prevent the phosphodiesterase enzymes from breaking down cAMP and cGMP in the cell. As a result, they increase the cAMP and cGMP, leading to an increase in intracellular calcium, which causes vasodilation and smooth muscle relaxation. There are four types of phosphodiesterase inhibitors, which have an effect on different locations in the body, depending on the specific phosphodiesterase enzyme they target. PDE5 inhibitors are commonly used for the treatment of erectile dysfunction and pulmonary hypertension. PDE4 inhibitors can be used to treat asthma, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, inflammatory bowel disease, and rheumatoid arthritis. PDE3 inhibitors are indicated for the treatment of heart failure, coronary heart disease, and to prevent myocardial infarction. Finally, nonspecific phosphodiesterase inhibitors are used in the treatment of asthma and chronic obstructive pulmonary disease.
Quiz yourself on Phosphodiesterase Inhibitors
31 Flashcards availableQuiz now!
Watch related videos:
Related linksPDE5 Inhibitors
cGMP-mediated Smooth Muscle Vasodilators
Resources for research and reference
Boswell-Smith, V., Spina, D., & Page, C. P. (2009). Phosphodiesterase inhibitors. British Journal of Pharmacology, 147(Suppl 1): S252–S257. DOI: 10.1038/sj.bjp.0706495
Caffeine for the Sustainment of Mental Task Performance. (2001). Institute of Medicine (US) Committee on Military Nutrition Research. Washington: National Academies Press. Retrieved August 26, 2020, from https://www.ncbi.nlm.nih.gov/books/NBK223802/
Elhwuegi A. S. (2016). The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History. Annals of Medical and Health Sciences Research, 6(3): 139–145. DOI: 10.4103/2141-9248.183943
Francis, S. H., Sekhar, K. R., Ke, H., & Corbin, J. D. (2010). Inhibition of Cyclic Nucleotide Phosphodiesterases by Methylxanthines and Related Compounds. Handbook of Experimental Pharmacology. DOI: 10.1007/978-3-642-13443-2_4
Ghofrani, H. A., Pepke-Zaba, J., Barbera, J. A., Channick, R., Keogh, A. M., Gomez-Sanchez, M. A., Kneussl, M., & Grimminger, F. (2004). Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. Journal of the American College of Cardiology, 43(12): S68–S72. DOI: 10.1016/j.jacc.2004.02.031
Huang, S. A. & Lie, J. D. (2013). Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. Pharmacy & Therapeutics, 38(7): 407–419. Retrieved August 26, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776492
Maggi, M., Filippi, S., Ledda, F., Magini, A., & Forti, G. (2000). Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. European Journal of Endocrinology, 143(2): 143-154. DOI: 10.1530/eje.0.1430143
Murphy, M., Demers, J., Ostroff, M., & Ostroff, J. (2018). Oral PDE5 Inhibitors for Erectile Dysfunction. U.S. Pharmacist. Retrieved August 26, 2020, from https://www.uspharmacist.com/article/oral-pde5-inhibitors-for-erectile-dysfunction
Saffon Cuartas, J. P., Sandoval-Salinas, C., Martínez, J. M., & Corredor, H. A. (2019). Treatment of Priapism Secondary to Drugs for Erectile Dysfunction. Advances in Urology, 2019. DOI: 10.1155/2019/6214921
Schmidt, D. T., Watson, N., Dent, G., Rühlmann, E., Branscheid, D., Magnussen, H., & Rabe, K. F. (2000). The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. British Journal of Pharmacology, 131(8): 1607–1618. DOI: 10.1038/sj.bjp.0703725
Theophylline. (2019). In MedlinePlus. Retrieved August 25, 2020, from https://medlineplus.gov/druginfo/meds/a681006.html
Torphy, T. J. & Undem, B. J. (1991). Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax, 46(7): 512–523. DOI: 10.1136/thx.46.7.512